Why Use an EDC for Animal Health Studies?

Episode Highlights

On the willingness of the Animal Health sector to move to electronic data capture: [1:40]

So, the willingness of the animal health medication research can be classified in either technology or costs. Technology usually means that the company needs to invest in equipment…. Then the cost is also a huge driving factor in switching studies destined for paper to EDC. Many smaller sponsors do not make provision for a software budget, or they will never be able to afford additional expenses for this.

So what’s the greatest improvement you’ve seen from running a trial on EDC compared to paper? [5:05]

Well, there’s no backlog in the data entry team and no risk of transcription errors. For our paper studies we perform double entry on most studies followed by an automated comparison and another manual check to check the percentage of data… So this process is eliminated and the data coordination department can focus now solely on the data quality.

What plans do you have for future studies that would typically run on paper? Is your goal to move everything to electronic data capture? [6:05]

Yes. It’s a goal of Clindata to get as many studies moved over to EDC, but for some cases EDC is just not feasible…. But for the majority of studies, we are actively working on to get studies transitioned to EDC.


Fred Martin 
Chief Product Officer | Medrio
Fred Martin has built a career in healthcare over the course of nearly two decades, and has developed healthcare systems, BI/Analytics solutions, workflow tools for hospitals, and more. He has served in Director of VP positions at companies including PointClickCare, Press Ganey, and Premier Healthcare Alliance. He brings broad experience in user-centered design and bridging consumer-centric front-end web applications and technology infrastructures to his role at Medrio. Fred holds an MBA from the University of Michigan, Ann Arbor; an MILR from Cornell University; and a BA from the University of Colorado, Boulder.

Jaco Kasselman 
Director of Animal Health | Clindata
Jaco Kasselman is an experienced clinical trials leader with a pharmaceutical background. Prior to his role with Clindata, Jaco held senior positions with IQVIA and Parexel. During the last six years with Clindata, Jaco has successfully focused on improving Animal Health processes for clinical trials.

Enter a topic, term or keyword below: